Germany is the leading medtech market in Europe, with a 22% market share. While funding for high-cost innovative medtech in Germany has evolved in recent years, there are still many challenges in securing reimbursement even as demand for these technologies surges. In an analysis published in Med Device Online, we explored how medtech companies should approach the reimbursement pathway for these devices when seeking to enter the German market.
Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...